UBS Upgrades Jazz Pharmaceuticals with Significant Price Target Increase
On May 19, UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals (JAZZ) from neutral to buy and raised the stock price target by 63% to $307. The upgrade is tied to an upcoming FDA decision on Ziihera for HER2-positive gastroesophageal cancer expected in August.
